

In-Hospital Use of Statins Is Associated with a Reduced with COVID-19

Cell Metabolism

32, 176-187.e4

DOI: [10.1016/j.cmet.2020.06.015](https://doi.org/10.1016/j.cmet.2020.06.015)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Commentary: Statins, COVID-19, and coronary artery disease: killing two birds with one stone. <i>Metabolism: Clinical and Experimental</i> , 2020, 113, 154375.	1.5	40
2	Statins-based prophylactic mouthwash and nasal spray may protect against COVID-19. <i>New Microbes and New Infections</i> , 2020, 37, 100751.	0.8	5
3	Effect of Corticosteroid Therapy on the Duration of SARS-CoV-2 Clearance in Patients with Mild COVID-19: A Retrospective Cohort Study. <i>Infectious Diseases and Therapy</i> , 2020, 9, 943-952.	1.8	19
4	Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. <i>Atherosclerosis</i> , 2020, 314, 58-62.	0.4	213
5	Statin Use and In-Hospital Mortality in Patients With Diabetes Mellitus and COVID-19. <i>Journal of the American Heart Association</i> , 2020, 9, e018475.	1.6	84
6	Vascular Events, Vascular Disease and Vascular Risk Factors—Strongly Intertwined with COVID-19. <i>Current Treatment Options in Neurology</i> , 2020, 22, 40.	0.7	10
7	Statin use is associated with lower disease severity in COVID-19 infection. <i>Scientific Reports</i> , 2020, 10, 17458.	1.6	93
8	Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action. <i>Internal and Emergency Medicine</i> , 2020, 15, 1573-1576.	1.0	43
9	Statin Treatment of COVID-19. <i>American Journal of Cardiology</i> , 2020, 136, 171-173.	0.7	9
10	FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. <i>Drug Resistance Updates</i> , 2020, 53, 100719.	6.5	110
11	Commentary: A Human Pluripotent Stem Cell-Based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids. <i>Frontiers in Endocrinology</i> , 2020, 11, 585922.	1.5	4
12	Targeting the renin-angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenges. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 29274-29282.	3.3	26
13	Statin therapy and risk of Alzheimer's and age-related neurodegenerative diseases. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12108.	1.8	43
14	Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol. <i>EMBO Journal</i> , 2020, 39, e106057.	3.5	203
15	Using "old" medications to fight new COVID-19: Re-purposing with a purpose. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 146, 41-42.	0.9	1
16	Teaching Old Drugs New Tricks: Statins for COVID-19?. <i>Cell Metabolism</i> , 2020, 32, 145-147.	7.2	29
17	Meta-analysis of Effect of Statins in Patients with COVID-19. <i>American Journal of Cardiology</i> , 2020, 134, 153-155.	0.7	149
18	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. <i>International Immunopharmacology</i> , 2020, 88, 106980.	1.7	31

#	ARTICLE	IF	CITATIONS
19	Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactions. <i>Pharmacological Research</i> , 2020, 161, 105250.	3.1	37
20	Statins and SARS-CoV-2 disease: Current concepts and possible benefits. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 2063-2067.	1.8	26
21	Statins in COVID-19: A new ray of hope. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2020, 49, 887-889.	0.8	2
22	COVID-19 is, in the end, an endothelial disease. <i>European Heart Journal</i> , 2020, 41, 3038-3044.	1.0	702
23	<scp>COVID</scp>â€19: biological factors in men's vulnerability. <i>Trends in Urology & Men's Health</i> , 2020, 11, 7.	0.2	7
24	Statin Use Is Associated with Decreased Risk of Invasive Mechanical Ventilation in COVID-19 Patients: A Preliminary Study. <i>Pathogens</i> , 2020, 9, 759.	1.2	46
25	Covidâ€19: From structure to therapeutic targeting in studying approved drugs and local DNA vaccination. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2020, 47, 1771-1773.	0.9	0
26	Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients. <i>American Journal of Cardiology</i> , 2020, 136, 149-155.	0.7	134
27	The Interplay Between Coagulation and Inflammation Pathways in COVID-19-Associated Respiratory Failure: A Narrative Review. <i>Pulmonary Therapy</i> , 2020, 6, 215-231.	1.1	16
28	COVID-19 and chronic renal disease: clinical characteristics and prognosis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2020, 113, 799-805.	0.2	41
29	Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 571-590.	1.0	34
30	Cardioâ€oncology care in the era of the coronavirus disease 2019 (COVIDâ€19) pandemic: An International Cardioâ€Oncology Society (ICOS) statement. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 480-504.	157.7	29
31	Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review. <i>Respiratory Medicine</i> , 2020, 171, 106114.	1.3	23
32	Protective Effects of CVD and DM Medications in SARS-CoV-2 Infection. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1296-1298.	0.3	7
33	Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults. <i>The Lancet Healthy Longevity</i> , 2020, 1, e55-e57.	2.0	60
34	The significance of hyperglycaemia and other comorbidities during the <scp>COVID</scp>â€19 pandemic. <i>Practical Diabetes</i> , 2020, 37, 157-169.	0.1	0
35	Osmotic Adaptation by Na ⁺ -Dependent Transporters and ACE2: Correlation with Hemostatic Crisis in COVID-19. <i>Biomedicines</i> , 2020, 8, 460.	1.4	11
36	The Neat Dance of COVID-19: NEAT1, DANCR, and Co-Modulated Cholinergic RNAs Link to Inflammation. <i>Frontiers in Immunology</i> , 2020, 11, 590870.	2.2	37

#	ARTICLE	IF	CITATIONS
37	SARS-CoV-2 and mitochondrial health: implications of lifestyle and ageing. <i>Immunity and Ageing</i> , 2020, 17, 33.	1.8	46
38	Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 157-164.	1.4	64
39	COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 1539-1545.	1.2	32
40	Letter to the Editor: Statins and COVID-19: Efficacy Still to Be Proven. <i>Hepatology</i> , 2021, 73, 875-875.	3.6	3
41	Metabolic adaptations of cells at the vascular-immune interface during atherosclerosis. <i>Molecular Aspects of Medicine</i> , 2021, 77, 100918.	2.7	13
42	Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?. , 2021, 219, 107703.		50
43	Large-Scale Multi-omic Analysis of COVID-19 Severity. <i>Cell Systems</i> , 2021, 12, 23-40.e7.	2.9	438
44	COVID-19 – A vascular disease. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 1-5.	2.3	254
45	Mechanisms of COVID-19-induced cardiovascular disease: Is sepsis or exosome the missing link?. <i>Journal of Cellular Physiology</i> , 2021, 236, 3366-3382.	2.0	21
46	Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: Results from the CORONADO study. <i>Diabetes and Metabolism</i> , 2021, 47, 101202.	1.4	66
47	A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor. , 2021, 221, 107750.		34
48	COVID-19 and diabetes mellitus: from pathophysiology to clinical management. <i>Nature Reviews Endocrinology</i> , 2021, 17, 11-30.	4.3	653
49	Genetic Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses. <i>Cell</i> , 2021, 184, 106-119.e14.	13.5	320
51	Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks. <i>Cell</i> , 2021, 184, 120-132.e14.	13.5	328
52	The benefit of statins in SARS-CoV-2 patients: further metabolic and prospective clinical studies are needed. <i>Endocrine</i> , 2021, 71, 270-272.	1.1	19
53	Integrating Proteomics for Facilitating Drug Identification and Repurposing During an Emerging Virus Pandemic. <i>ACS Infectious Diseases</i> , 2021, 7, 1303-1316.	1.8	1
54	Cholesterol, inflammation, and phospholipids: COVID-19 share traits with cardiovascular disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2021, 1866, 158839.	1.2	3
55	MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 129-135.	2.0	37

#	ARTICLE	IF	CITATIONS
56	A pharmacological framework for integrating treating the host, drug repurposing and the damage response framework in COVID-19. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 875-885.	1.1	8
57	Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications. <i>Molecular Neurobiology</i> , 2021, 58, 106-117.	1.9	32
58	Evaluation of pheniramine maleate and zofenopril in reducing renal damage induced by unilateral ureter obstruction. An experimental study. <i>Archives of Medical Science</i> , 2021, 17, 812-817.	0.4	0
59	Effects of statins on cytokines levels in gingival crevicular fluid and saliva and on clinical periodontal parameters of middle-aged and elderly patients with type 2 diabetes mellitus. <i>PLoS ONE</i> , 2021, 16, e0244806.	1.1	8
60	Drugmonizome and Drugmonizome-ML: integration and abstraction of small molecule attributes for drug enrichment analysis and machine learning. <i>Database: the Journal of Biological Databases and Curation</i> , 2021, 2021, .	1.4	19
61	The use of statins was associated with reduced COVID-19 mortality: a systematic review and meta-analysis. <i>Annals of Medicine</i> , 2021, 53, 874-884.	1.5	33
62	Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic. <i>Rheumatology International</i> , 2021, 41, 243-256.	1.5	53
63	Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 599334.	1.1	15
65	Protective Effects of Statins Administration in European and North American Patients Infected with COVID-19: A Meta-Analysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 392-399.	1.5	34
66	Lipids, statins and susceptibility to SARS-CoV-2 and influenza A viruses. <i>Microbiology Australia</i> , 2021, 42, 87.	0.1	2
67	Vigilance on New-Onset Atherosclerosis Following SARS-CoV-2 Infection. <i>Frontiers in Medicine</i> , 2020, 7, 629413.	1.2	22
68	Statins in patients with COVID-19: a retrospective cohort study in Iranian COVID-19 patients. <i>Translational Medicine Communications</i> , 2021, 6, 3.	0.5	41
69	Association of In-hospital Use of Statins, Aspirin, and Renin-Angiotensin-Aldosterone Inhibitors with Mortality and ICU Admission Due to COVID-19. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1327, 205-214.	0.8	13
70	Transcriptome analysis of cepharanthine against a SARS-CoV-2-related coronavirus. <i>Briefings in Bioinformatics</i> , 2021, 22, 1378-1386.	3.2	39
71	COVID-19 Is an Endothelial Disease: Implications of Nitric Oxide. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1321, 109-113.	0.8	6
72	Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkaa081.	0.3	36
73	Impact of obesity and SARS-CoV-2 infection: implications for host defence - a living review. <i>Oxford Open Immunology</i> , 2021, 2, iqab001.	1.2	9
74	The Role of Bioactive Lipids and Statins in COVID-19 Disease and Their Use in the Therapeutic Approach. Are These Effective?. <i>Journal of Biosciences and Medicines</i> , 2021, 09, 143-173.	0.1	0

#	ARTICLE	IF	CITATIONS
76	Statin use and clinical outcomes in patients with COVID-19: An updated systematic review and meta-analysis. <i>Postgraduate Medical Journal</i> , 2022, 98, 354-359.	0.9	38
77	In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis. <i>Pharmacological Reports</i> , 2021, 73, 769-780.	1.5	51
78	Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. <i>Diabetologia</i> , 2021, 64, 778-794.	2.9	120
79	Decreased Mortality Rate Among COVID-19 Patients Prescribed Statins: Data From Electronic Health Records in the US. <i>Frontiers in Medicine</i> , 2021, 8, 639804.	1.2	18
81	How Do Inflammatory Mediators, Immune Response and Air Pollution Contribute to COVID-19 Disease Severity? A Lesson to Learn. <i>Life</i> , 2021, 11, 182.	1.1	11
83	Statin Therapy and the Risk of COVID-19: A Cohort Study of the National Health Insurance Service in South Korea. <i>Journal of Personalized Medicine</i> , 2021, 11, 116.	1.1	19
84	Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. <i>Nature Communications</i> , 2021, 12, 1325.	5.8	133
85	Diabète et COVID-19: les leçons de CORONADO. <i>Medecine Des Maladies Metaboliques</i> , 2021, 15, 15-23.	0.1	2
86	Renin-angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies. <i>Journal of Hypertension</i> , 2021, 39, 784-794.	0.3	34
87	Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. <i>International Reviews of Immunology</i> , 2022, 41, 217-230.	1.5	93
88	The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19. <i>Cell Metabolism</i> , 2021, 33, 258-269.e3.	7.2	87
89	COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies. <i>Molecular Biology Reports</i> , 2021, 48, 2917-2928.	1.0	7
90	Bottom-up analysis of emergent properties of N-acetylcysteine as an adjuvant therapy for COVID-19. <i>World Journal of Virology</i> , 2021, 10, 34-52.	1.3	14
91	Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 429-460.	1.0	22
92	The advantages of drug treatment with statins in patients with SARS-CoV-2 infection. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 958-965.	1.0	7
93	Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry. <i>Drugs</i> , 2021, 81, 685-695.	4.9	28
94	Statin therapy is associated with less ICU admissions in COVID-19 patients. A preliminary analysis of the current observations. <i>Minerva Anestesiologica</i> , 2021, 87, 951-952.	0.6	1
95	Considerations of the effects of commonly investigated drugs for COVID-19 in the cholesterol synthesis pathway. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1-6.	0.9	2

#	ARTICLE	IF	CITATIONS
96	Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning. <i>Cell Metabolism</i> , 2021, 33, 479-498.	7.2	179
97	An Overview of Current Knowledge of Deadly CoVs and Their Interface with Innate Immunity. <i>Viruses</i> , 2021, 13, 560.	1.5	15
98	Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment. <i>Atherosclerosis</i> , 2021, 320, 53-60.	0.4	25
99	Diabetes mellitus in combination with COVID-19: modern views on therapy. <i>Reproductive Endocrinology</i> , 2021, , 8-20.	0.0	0
100	Angiotensin-converting enzyme 2 and kidney diseases in the era of coronavirus disease 2019. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 247-262.	0.7	3
103	Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration. <i>Frontiers in Immunology</i> , 2021, 12, 589095.	2.2	102
104	Drug Repurposing for COVID-19 Treatment by Integrating Network Pharmacology and Transcriptomics. <i>Pharmaceutics</i> , 2021, 13, 545.	2.0	17
105	SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation. <i>ELife</i> , 2021, 10, .	2.8	160
107	Statin Use Is Associated with a Decreased Risk of Mortality among Patients with COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 1450.	1.0	15
108	Association Between Chronic Statin Use and 30-Day Mortality in Hospitalized Patients With COVID-19. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 442-446.	1.2	9
110	Role of Statins in Coronavirus-Related Disease (COVID-19): A Retrospective Cohort Study in Northern Italy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 355-364.	1.0	5
111	Development and validation of a risk score using complete blood count to predict in-hospital mortality in COVID-19 patients. <i>Med</i> , 2021, 2, 435-447.e4.	2.2	20
112	Dissecting lipid metabolism alterations in SARS-CoV-2. <i>Progress in Lipid Research</i> , 2021, 82, 101092.	5.3	71
113	Lipid homeostasis and mevalonate pathway in COVID-19: Basic concepts and potential therapeutic targets. <i>Progress in Lipid Research</i> , 2021, 82, 101099.	5.3	24
114	COVID-19: Direct and Indirect Mechanisms of Statins. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4177.	1.8	34
115	A risk score based on baseline risk factors for predicting mortality in COVID-19 patients. <i>Current Medical Research and Opinion</i> , 2021, 37, 917-927.	0.9	11
116	Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 153, 72-85.	0.9	12
117	Prior Statin Use and Risk of Mortality and Severe Disease From Coronavirus Disease 2019: A Systematic Review and Meta-analysis. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab284.	0.4	11

#	ARTICLE	IF	CITATIONS
118	Association Between Statin Use Prior to Admission and Lower Coronavirus Disease 2019 (COVID-19) Severity in Patients With Cardiovascular Disease or Risk Factors. <i>Circulation Journal</i> , 2021, 85, 939-943.	0.7	12
119	Lipid-lowering therapy in high cardiovascular risk patients during COVID-19 pandemic: keep focused on the target. <i>Monaldi Archives for Chest Disease</i> , 2021, 91, .	0.3	0
120	Therapeutic Potential of Exploiting Autophagy Cascade Against Coronavirus Infection. <i>Frontiers in Microbiology</i> , 2021, 12, 675419.	1.5	25
121	Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery. <i>Frontiers in Pharmacology</i> , 2021, 12, 660710.	1.6	15
122	Increased mortality risk associated with statins in the CORONADO study. <i>Diabetes and Metabolism</i> , 2021, 47, 101250.	1.4	3
123	SARS-CoV-2 Infection Is Associated with Reduced KrÄ¼ppel-like Factor 2 in Human Lung Autopsy. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2021, 65, 222-226.	1.4	5
124	Association between antecedent statin use and severe disease outcomes in COVID-19: A retrospective study with propensity score matching. <i>Journal of Clinical Lipidology</i> , 2021, 15, 451-459.	0.6	22
126	Drug Repurposing for the Treatment of COVID-19: A Knowledge Graph Approach. <i>Advanced Therapeutics</i> , 2021, 4, 2100055.	1.6	12
127	Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 35-44.	0.6	4
128	Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2841-2850.	1.4	15
129	Decreased Low-Density Lipoprotein Cholesterol Level Indicates Poor Prognosis of Severe and Critical COVID-19 Patients: A Retrospective, Single-Center Study. <i>Frontiers in Medicine</i> , 2021, 8, 585851.	1.2	14
130	Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: a systematic review and meta-analysis. <i>Archives of Medical Science</i> , 2021, 17, 579-595.	0.4	61
131	Therapeutic Agents Against COVID-19 with Clinical Evidence. <i>Current Pharmaceutical Design</i> , 2021, 27, 1608-1617.	0.9	4
132	Use of Renin-Angiotensin-Aldosterone System Inhibitors and Severe COVID-19 Outcomes in Patients with Hypertension: A Nationwide Cohort Study. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 430-438.	1.8	4
133	Prevalence and risk factors of thrombotic events on patients with COVID-19: a systematic review and meta-analysis. <i>Thrombosis Journal</i> , 2021, 19, 32.	0.9	49
134	Response to Plat and Mensink. <i>British Journal of Nutrition</i> , 2021, , 1-2.	1.2	0
135	Impact of COVID-19 in Liver Disease Progression. <i>Hepatology Communications</i> , 2021, 5, 1138-1150.	2.0	39
136	Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, e102-e109.	1.7	22

#	ARTICLE	IF	CITATIONS
137	Association between cardiometabolic risk factors and COVID-19 susceptibility, severity and mortality: a review. <i>Journal of Diabetes and Metabolic Disorders</i> , 2021, 20, 1743-1765.	0.8	21
138	Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. <i>Pharmacological Reviews</i> , 2021, 73, 924-967.	7.1	359
139	The protective association between statins use and adverse outcomes among COVID-19 patients: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0253576.	1.1	26
140	Promising effects of atorvastatin on mortality and need for mechanical ventilation in patients with severe COVID-19; a retrospective cohort study. <i>International Journal of Clinical Practice</i> , 2021, 75, e14434.	0.8	10
141	Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome. <i>Cells</i> , 2021, 10, 1412.	1.8	6
142	The impact of atherosclerotic cardiovascular disease, dyslipidaemia and lipid lowering therapy on Coronavirus disease 2019 outcomes. <i>Current Opinion in Lipidology</i> , 2021, Publish Ahead of Print, 231-243.	1.2	2
143	COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course. <i>Frontiers in Endocrinology</i> , 2021, 12, 649525.	1.5	124
144	Statin and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 1662-1670.	1.1	32
145	Statin and mortality in COVID-19: a systematic review and meta-analysis of pooled adjusted effect estimates from propensity-matched cohorts. <i>Postgraduate Medical Journal</i> , 2022, 98, 503-508.	0.9	22
146	Dyslipidemia Is Related to Mortality in Critical Patients With Coronavirus Disease 2019: A Retrospective Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 611526.	1.5	12
147	Studying the Effect of Taking Statins before Infection in the Severity Reduction of COVID-19 with Machine Learning. <i>BioMed Research International</i> , 2021, 2021, 1-12.	0.9	21
148	Statins in COVID-19 Therapy. <i>Life</i> , 2021, 11, 565.	1.1	3
149	Plausible Positive Effects of Statins in COVID-19 Patient. <i>Cardiovascular Toxicology</i> , 2021, 21, 781-789.	1.1	6
150	Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: Findings from the American Heart Association's COVID-19 Cardiovascular Disease Registry. <i>PLoS ONE</i> , 2021, 16, e0254635.	1.1	33
151	Statins and clinical outcomes in hospitalized COVID-19 patients with and without Diabetes Mellitus: a retrospective cohort study with propensity score matching. <i>Cardiovascular Diabetology</i> , 2021, 20, 140.	2.7	16
152	Preadmission Statin Therapy and Clinical Outcome in Hospitalized Patients With COVID-19: An Italian Multicenter Observational Study. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, e94-e100.	0.8	11
153	Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. <i>Immunity</i> , 2021, 54, 1463-1477.e11.	6.6	179
154	Effects of Statins on Renin-Angiotensin System. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 80.	0.8	7

#	ARTICLE	IF	CITATIONS
156	Basic mechanisms of SARS-CoV-2 infection. What endocrine systems could be implicated?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 137-150.	2.6	15
157	Impact of statins in patients with COVID-19. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 637-640.	0.4	9
158	The zinc finger transcription factor, KLF2, protects against COVID-19 associated endothelial dysfunction. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 266.	7.1	33
159	Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1493-1503.	0.9	17
161	Association between coronary artery calcifications and 6-month mortality in hospitalized patients with COVID-19. <i>Diagnostic and Interventional Imaging</i> , 2021, 102, 717-725.	1.8	11
162	COVID-19 and Acute Coronary Syndromes: From Pathophysiology to Clinical Perspectives. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-13.	1.9	25
163	NICEdrug.ch, a workflow for rational drug design and systems-level analysis of drug metabolism. <i>ELife</i> , 2021, 10, .	2.8	8
164	Predictors of Severe COVID-19 in Patients With Diabetes: A Multicenter Review. <i>Endocrine Practice</i> , 2021, 27, 842-849.	1.1	10
165	Immune Protection of Stem Cell-Derived Islet Cell Therapy for Treating Diabetes. <i>Frontiers in Endocrinology</i> , 2021, 12, 716625.	1.5	16
167	Pharmacological Predictors of Morbidity and Mortality in COVID-19. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1286-1300.	1.0	16
168	The Association Between the Use of Statins and Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-analysis. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 167-181.	1.0	24
169	Statin use and mortality in COVID-19 patients: Updated systematic review and meta-analysis. <i>Atherosclerosis</i> , 2021, 330, 114-121.	0.4	35
170	Dyslipidemia in breast cancer patients increases the risk of SAR-CoV-2 infection. <i>Infection, Genetics and Evolution</i> , 2021, 92, 104883.	1.0	4
171	Pharmacotherapeutic agents for the management of COVID-19 patients with preexisting cardiovascular disease. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2455-2474.	0.9	2
172	Cholesterol-induced toxicity: An integrated view of the role of cholesterol in multiple diseases. <i>Cell Metabolism</i> , 2021, 33, 1911-1925.	7.2	91
174	Prognostic Value of Leucocyte to High-Density Lipoprotein-Cholesterol Ratios in COVID-19 Patients and the Diabetes Subgroup. <i>Frontiers in Endocrinology</i> , 2021, 12, 727419.	1.5	7
175	Efficacy of Statin Therapy in Patients with Hospital Admission for COVID-19. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 1165-1173.	1.3	15
176	A Comprehensive Insight into the Role of Exosomes in Viral Infection: Dual Faces Bearing Different Functions. <i>Pharmaceutics</i> , 2021, 13, 1405.	2.0	35

#	ARTICLE	IF	CITATIONS
177	Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry. <i>Molecular Medicine</i> , 2021, 27, 105.	1.9	18
179	New Strategies to Improve Patient Adherence to Medications for Noncommunicable Diseases During and After the COVID-19 Era Identified via a Literature Review. <i>Journal of Multidisciplinary Healthcare</i> , 2021, Volume 14, 2453-2465.	1.1	16
180	Letter to the Editor in response to "Response to Kovanen PT, et al. Letter to the Editor" for original article COVID-19 increases risk of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD. <i>American Journal of Preventive Cardiology</i> , 2021, 7, 100225.	1.3	2
181	Improved COVID-19 Outcomes following Statin Therapy: An Updated Systematic Review and Meta-analysis. <i>BioMed Research International</i> , 2021, 2021, 1-20.	0.9	33
182	Statins reduce mortality in patients with COVID-19: an updated meta-analysis of 147,824 patients. <i>International Journal of Infectious Diseases</i> , 2021, 110, 374-381.	1.5	45
183	The roles of lipids in SARS-CoV-2 viral replication and the host immune response. <i>Journal of Lipid Research</i> , 2021, 62, 100129.	2.0	47
184	Editorial: Targeting Lipid Rafts as a Strategy Against Infection and Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 748905.	1.8	1
185	Clinical Characteristics, Care Trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer Patients: A Multicenter Cohort Study. <i>Cancers</i> , 2021, 13, 4749.	1.7	13
186	Cardiovascular involvement in patients with 2019 novel coronavirus disease. <i>Journal of Translational Internal Medicine</i> , 2021, 9, 152-160.	1.0	5
187	Direct Activation of Endothelial Cells by SARS-CoV-2 Nucleocapsid Protein Is Blocked by Simvastatin. <i>Journal of Virology</i> , 2021, 95, e0139621.	1.5	52
188	The protective role of statins in COVID-19 patients: a retrospective observational study. <i>Translational Medicine Communications</i> , 2021, 6, 22.	0.5	16
189	Repurposing Cardio-Metabolic Drugs to Fight Covid19. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 419-423.	1.0	1
190	Coronaviruses, cholesterol and statins: Involvement and application for Covid-19. <i>Biochimie</i> , 2021, 189, 51-64.	1.3	11
191	Know your enemy and know yourself " the case of SARS-CoV-2 host factors. <i>Current Opinion in Virology</i> , 2021, 50, 159-170.	2.6	9
192	Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial. <i>IJC Heart and Vasculature</i> , 2021, 36, 100875.	0.6	15
193	Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies. <i>Diabetes and Metabolism</i> , 2021, 47, 101220.	1.4	38
194	The role of lovastatin in the attenuation of COVID-19. <i>International Immunopharmacology</i> , 2021, 101, 108192.	1.7	17
195	COVID-19 and Thromboinflammation: Is There a Role for Statins?. <i>Clinics</i> , 2021, 76, e2518.	0.6	9

#	ARTICLE	IF	CITATIONS
196	Dependence of SARS-CoV-2 infection on cholesterol-rich lipid raft and endosomal acidification. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 1933-1943.	1.9	69
198	COVID-19 Antiviral and Treatment Candidates: Current Status. <i>Immune Network</i> , 2021, 21, e7.	1.6	8
199	Obesity and severe coronavirus disease 2019: molecular mechanisms, paths forward, and therapeutic opportunities. <i>Theranostics</i> , 2021, 11, 8234-8253.	4.6	16
200	Statins as an adjunctive therapy for COVID-19: the biological and clinical plausibility. <i>Immunopharmacology and Immunotoxicology</i> , 2021, 43, 37-50.	1.1	17
201	COVID-19 Epidemic and Opening of the Schools: Artificial Intelligence-Based Long-Term Adaptive Policy Making to Control the Pandemic Diseases. <i>IEEE Access</i> , 2021, 9, 68461-68471.	2.6	25
203	Dysregulation of the mevalonate pathway during SARS-CoV-2 infection: An in silico study. <i>Journal of Medical Virology</i> , 2021, 93, 2396-2405.	2.5	12
204	COVID-19, host response treatment, and the need for political leadership. <i>Journal of Public Health Policy</i> , 2021, 42, 6-14.	1.0	12
210	Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19): a nationwide cohort study. <i>BMJ Open</i> , 2020, 10, e044421.	0.8	54
211	Investigations of Pathologists as a Key to Understanding Coronavirus Disease 2019. <i>Pathobiology</i> , 2021, 88, 11-14.	1.9	7
212	The Potential Role of Dyslipidemia in COVID-19 Severity: an Umbrella Review of Systematic Reviews. <i>Journal of Lipid and Atherosclerosis</i> , 2020, 9, 435.	1.1	45
213	International register – Dynamics analysis of comorbidities in SARS-CoV-2 survivors (AKTIV) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3	0.4	13
214	Commonalities Between COVID-19 and Radiation Injury. <i>Radiation Research</i> , 2020, 195, 1-24.	0.7	23
216	COVID-19: A Therapeutic Approach Based on Pathophysiological Staging. <i>Open Respiratory Medicine Journal</i> , 2020, 14, 32-37.	1.3	1
217	Associations of Medications With Lower Odds of Typical COVID-19 Symptoms: Cross-Sectional Symptom Surveillance Study. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e22521.	1.2	9
218	Confronting the threat of SARS-CoV-2: Realities, challenges and therapeutic strategies (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 155.	0.8	6
219	Current status of COVID-19 treatment: An opinion review. <i>World Journal of Virology</i> , 2020, 9, 27-37.	1.3	12
220	Obesity and diabetes as comorbidities for COVID-19: Underlying mechanisms and the role of viral-bacterial interactions. <i>ELife</i> , 2020, 9, .	2.8	69
221	Impact of computational approaches in the fight against COVID-19: an AI guided review of 17 000 studies. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	20

#	ARTICLE	IF	CITATIONS
223	The structure of the drug therapy prescription to cardiac patients during the primary care: the lessons of the OZIRKA study. <i>Hypertension</i> , 2021, 14, 11-20.	0.2	1
224	A historical cohort study to investigation of statins safety in COVID-19 hospitalized patients. <i>Therapie</i> , 2022, 77, 453-460.	0.6	3
225	Anti-flavivirus Properties of Lipid-Lowering Drugs. <i>Frontiers in Physiology</i> , 2021, 12, 749770.	1.3	18
226	Statins and SARS-CoV-2 Infection: Results of a Population-Based Prospective Cohort Study of 469,749 Adults From 2 Canadian Provinces. <i>Journal of the American Heart Association</i> , 2021, 10, e022330.	1.6	11
227	Statin Use and COVID-19 Infectivity and Severity in South Korea: Two Population-Based Nationwide Cohort Studies. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e29379.	1.2	8
228	Metabolic Reprogramming in COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11475.	1.8	34
229	HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: A registry-based cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003820.	3.9	29
230	All-cause mortality in COVID-19 patients receiving statin therapy: analysis of veterans affairs database cohort study. <i>Internal and Emergency Medicine</i> , 2022, 17, 685-694.	1.0	10
231	Pro a pÅ™edem probran½ souboj proti PCSK9 inhibitorÅ™m. <i>Vnitřni Lekarstvi</i> , 2021, 67, 3-8.	0.1	0
232	Association of Statins and 28-Day Mortality Rates in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2022, 225, 19-29.	1.9	19
233	An antibody-based proximity labeling map reveals mechanisms of SARS-CoV-2 inhibition of antiviral immunity. <i>Cell Chemical Biology</i> , 2022, 29, 5-18.e6.	2.5	26
234	The Multifaceted Biology of PCSK9. <i>Endocrine Reviews</i> , 2022, 43, 558-582.	8.9	75
235	Drugs and liver injury: a not to be overlooked binomial in COVID-19. <i>Journal of Chemotherapy</i> , 2022, 34, 207-220.	0.7	3
236	Association Analysis of Hyperlipidemia with the 28-Day All-Cause mortality of COVID-19 in Hospitalized Patients. <i>Chinese Medical Sciences Journal</i> , 2019, 36, 15.	0.2	3
240	Did our pharmacological strategy for COVID-19 fail?. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00866.	1.1	2
241	Could Statin Therapy Be Useful in Patients With Coronavirus Disease 2019 (COVID-19)?. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 775749.	1.1	10
242	Statins: unexpected help in COVID-19. <i>Arterial Hypertension (Russian Federation)</i> , 2020, 26, 509-517.	0.1	2
243	Current Treatments of Coronavirus Disease 2019 in Elderly. <i>Korean Journal of Clinical Geriatrics</i> , 2020, 21, 54-64.	0.3	1

#	ARTICLE	IF	CITATIONS
244	Retrospective analysis of clinical outcomes of patients with COVID-19 depending on receiving antihypertensive, lipid-lowering and antihypertensive therapy. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 1193-1202.	0.2	0
245	Newly-Diagnosed Diabetes and Sustained Hyperglycemia are Associated with Poorer Outcomes in COVID-19 Inpatients Without Pre-Existing Diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 4469-4482.	1.1	5
246	Diabetes mellitus and COVID-19: review of a lethal interaction from the cellular and molecular level to the bedside. <i>Expert Review of Endocrinology and Metabolism</i> , 2022, 17, 1-19.	1.2	2
247	Association of clinical characteristics, antidiabetic and cardiovascular agents with diabetes mellitus and COVID-19: a 7-month follow-up cohort study. <i>Journal of Diabetes and Metabolic Disorders</i> , 2021, 20, 1-11.	0.8	16
248	The impact of statins on the course of a new coronavirus infection: myth or reality?. <i>Ä¼no-Rossijskij Ä¼urnal TerapevtiÄ¼eskoj Praktiki</i> , 2020, 1, 102-108.	0.1	1
249	CRITICAL CARE COVID-19 MANAGEMENT PROTOCOL: CLINICAL CASE. <i>Proceedings of the Shevchenko Scientific Society Medical Sciences</i> , 2020, 62, .	0.0	1
252	COVID Cardiovascular Illness. , 2021, , 99-109.		0
253	Risk factors for COVID-19 progression and mortality in hospitalized patients without pre-existing comorbidities. <i>Journal of Infection and Public Health</i> , 2022, 15, 13-20.	1.9	30
254	COVID-19, the Pandemic of the Century and Its Impact on Cardiovascular Diseases. <i>Cardiology Discovery</i> , 2021, 1, 233-258.	0.6	6
255	COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting EnzymeÄ², Mutual Effects and Pharmacotherapy. <i>Frontiers in Endocrinology</i> , 2021, 12, 772865.	1.5	15
256	Metabolic imbalance of T cells in COVID-19 is hallmarked by basigin and mitigated by dexamethasone. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	25
257	Acid suppressant use in association with incidence and severe outcomes of COVID-19: a systematic review and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 383-391.	0.8	11
258	Regulating monocyte infiltration and differentiation: Providing new therapies for colorectal cancer patients with COVID-19. <i>World Journal of Clinical Cases</i> , 2021, 9, 10392-10399.	0.3	0
259	DÄ°YABET VE COVID -19. <i>Ankara EÄ¼itim Ve AraÄ¼t±rma Hastanesi TÄ±p Dergisi</i> , 2022, 54, 471-478.	0.1	0
260	LDLR dysfunction induces LDL accumulation and promotes pulmonary fibrosis. <i>Clinical and Translational Medicine</i> , 2022, 12, e711.	1.7	14
261	Exosomes and COVID-19: challenges and opportunities. <i>Comparative Clinical Pathology</i> , 2022, 31, 347-354.	0.3	12
262	Interconnections between Inflammageing and Immunosenescence during Ageing. <i>Cells</i> , 2022, 11, 359.	1.8	70
263	Efficiency of high-intensity therapy with rosuvastatin for secondary prevention of cardiovascular complications in patients with a very high risk. <i>Atherothrombosis</i> , 2022, 11, 56-75.	0.1	0

#	ARTICLE	IF	CITATIONS
265	Vascular endotheliitis associated with infections: Its pathogenetic role and therapeutic implication. <i>Biochemical Pharmacology</i> , 2022, 197, 114909.	2.0	19
266	Relationship Between Blood Lipid Levels and Mortality in Hospitalized COVID-19 Patients. <i>Angiology</i> , 2022, 73, 724-733.	0.8	8
267	The association of statins use with survival of patients with COVID-19. <i>Journal of Cardiology</i> , 2022, 79, 494-500.	0.8	13
268	Fluvastatin mitigates SARS-CoV-2 infection in human lung cells. <i>IScience</i> , 2021, 24, 103469.	1.9	17
269	Cholesterol-Rich Lipid Rafts as Platforms for SARS-CoV-2 Entry. <i>Frontiers in Immunology</i> , 2021, 12, 796855.	2.2	63
270	THE VALUE OF A REGIONAL 'LIVING' COVID-19 REGISTRY AND THE CHALLENGES OF KEEPING IT ALIVE. <i>Perspectives in Health Information Management / AHIMA, American Health Information Management Association</i> , 2021, 18, 1d.	0.0	0
271	An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. <i>Drug Resistance Updates</i> , 2021, 59, 100794.	6.5	175
272	The Potential Impact of Statins in the Treatment of Patients with COVID-19 Infection. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1352, 149-158.	0.8	0
273	Anesthesia and intensive care for patients with COVID-19. <i>Russian Federation of anesthesiologists and reanimatologists guidelines. Alexander Saltanov Intensive Care Herald</i> , 2022, , 5-140.	0.2	7
274	COVID-19 and Diabetes Outcomes: Rationale for and Updates from the CORONADO Study. <i>Current Diabetes Reports</i> , 2022, 22, 53-63.	1.7	14
275	Statin Use in COVID-19 Hospitalized Patients and Outcomes: A Retrospective Study. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 820260.	1.1	27
276	Multi-Modal Hospital Treatment Protocol for COVID-19 Infection: Clinical and Scientific Rationale. <i>Journal of Clinical Medicine Research</i> , 2022, 14, 53-79.	0.6	4
277	Simvastatin Downregulates the SARS-CoV-2-Induced Inflammatory Response and Impairs Viral Infection Through Disruption of Lipid Rafts. <i>Frontiers in Immunology</i> , 2022, 13, 820131.	2.2	29
278	Using a Systems Approach to Explore the Mechanisms of Interaction Between Severe Covid-19 and Its Coronary Heart Disease Complications. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 737592.	1.1	1
279	Discontinuation of atorvastatin use in hospital is associated with increased risk of mortality in COVID-19 patients. <i>Journal of Hospital Medicine</i> , 2022, 17, 169-175.	0.7	11
280	Coronary artery calcifications and 6-month mortality in patients with COVID-19 without known atheromatous disease. <i>Archives of Cardiovascular Diseases</i> , 2022, , .	0.7	2
281	New laboratory evidence for the association between endothelial dysfunction and COVID-19 disease progression. <i>Journal of Medical Virology</i> , 2022, 94, 3112-3120.	2.5	12
283	Atorvastatin Reduces the Severity of COVID-19: A Nationwide, Total Population-Based, Case-Control Study. <i>Covid</i> , 2022, 2, 398-406.	0.7	3

#	ARTICLE	IF	CITATIONS
284	Autophagy Modulators in Coronavirus Diseases: A Double Strike in Viral Burden and Inflammation. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 845368.	1.8	10
285	Atorvastatin: old friend in the light of novel coronavirus infection's pandemic. <i>Meditinskiy Sovet</i> , 2022, , 82-88.	0.1	0
286	The Potential of Rosuvastatin in Stabilizing Lipid Profile and Improving Clinical Outcomes in Covid-19 Patients with Coronary Heart Disease. <i>Nusantara Medical Science Journal</i> , 0, , 54-65.	0.0	0
287	Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study. <i>ELife</i> , 2021, 10, .	2.8	49
288	Statin Use and In-hospital Mortality in Patients with COVID-19 and Coronary Heart Disease. <i>Scientific Reports</i> , 2021, 11, 23874.	1.6	6
289	Potential Contribution of Climate Conditions on COVID-19 Pandemic Transmission over West and North African Countries. <i>Atmosphere</i> , 2022, 13, 34.	1.0	4
290	The Identikit of Patient at Risk for Severe COVID-19 and Death: The Dysregulation of Renin-Angiotensin System as the Common Theme. <i>Journal of Clinical Medicine</i> , 2021, 10, 5883.	1.0	3
291	Impact of optimal therapy for noncommunicable diseases on the course and outcome of COVID-19 inpatients. <i>Russian Journal of Cardiology</i> , 2022, 27, 4845.	0.4	2
292	Computational prediction of the molecular mechanism of statin group of drugs against SARS-CoV-2 pathogenesis. <i>Scientific Reports</i> , 2022, 12, 6241.	1.6	12
293	Association of statin and/or renin-angiotensin-aldosterone system modulating therapy with mortality in adults with diabetes admitted to hospital with COVID-19: A retrospective multicentre European study. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102484.	1.8	6
295	The Impact of Cardiovascular Risk Factors on the Course of COVID-19. <i>Journal of Clinical Medicine</i> , 2022, 11, 2250.	1.0	6
300	Cyclodextrins as promising therapeutics against cholesterol overload. , 2022, , 927-967.		1
301	Association of testosterone therapy with disease progression in older males with COVID-19. <i>Andrology</i> , 2022, 10, 1057-1066.	1.9	9
302	Neurological aspects of SARS-CoV-2 infection: lipoproteins and exosomes as Trojan horses. <i>Trends in Endocrinology and Metabolism</i> , 2022, 33, 554-568.	3.1	15
303	Impact Of Metabolic Risk Factors On Covid-19 Clinical Outcomes: An Extensive Review. <i>Current Cardiology Reviews</i> , 2022, 18, .	0.6	1
304	Effects of statins on the risks of ischemic stroke and heart disease in human immunodeficiency virus infection, influenza and severe acute respiratory syndrome-associated coronavirus: respiratory virus infection with steroid use. <i>Postgraduate Medicine</i> , 2022, , 1-9.	0.9	0
305	Factors associated with anti-SARS-CoV-2 antibody titres 3 months post-vaccination with the second dose of BNT162b2 vaccine: a longitudinal observational cohort study in western Greece. <i>BMJ Open</i> , 2022, 12, e057084.	0.8	24
306	Use of poststroke medications and COVID-19-associated mortality. <i>Neurology India</i> , 2022, 70, 812.	0.2	0

#	ARTICLE	IF	CITATIONS
307	Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	12
308	Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID-19: A Nationwide Matched Population-Based Cohort Study. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	13
310	Biological Actions, Implications, and Cautions of Statins Therapy in COVID-19. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	5
311	Enzymes in the time of COVID-19: An overview about the effects in the human body, enzyme market, and perspectives for new drugs. <i>Medicinal Research Reviews</i> , 2022, 42, 2126-2167.	5.0	4
312	Plasma lipid profile: a predictive marker of disease severity among COVID-19 patients—an opportunity for low-income countries. <i>Drugs and Therapy Perspectives</i> , 2022, 38, 286-291.	0.3	3
313	Medications Associated with Lower Mortality in a SARS-CoV-2 Positive Cohort of 26,508 Veterans. <i>Journal of General Internal Medicine</i> , 2022, 37, 4144-4152.	1.3	5
314	The Effect of Statins on Clinical Outcome Among Hospitalized Patients With COVID-19: A Multi-Centric Cohort Study. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	24
315	Can iron, zinc, copper and selenium status be a prognostic determinant in COVID-19 patients?. <i>Environmental Toxicology and Pharmacology</i> , 2022, 95, 103937.	2.0	12
316	Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond. <i>Current Atherosclerosis Reports</i> , 2022, 24, 821-830.	2.0	29
317	A Review of COVID-19 in Relation to Metabolic Syndrome: Obesity, Hypertension, Diabetes, and Dyslipidemia. <i>Cureus</i> , 2022, , .	0.2	12
318	The impact of HMG-CoA reductase inhibitors use on the clinical outcomes in critically ill patients with COVID-19: A multicenter, cohort study. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	4
319	The role of platelets, neutrophils and endothelium in COVID-19 infection. <i>Expert Review of Hematology</i> , 2022, 15, 727-745.	1.0	7
320	Effects of Statins on Outcomes in Hispanic Patients with COVID-19. <i>Journal of Investigative Medicine</i> , 2022, 70, 1697-1703.	0.7	2
321	Lipid Raft Integrity and Cellular Cholesterol Homeostasis Are Critical for SARS-CoV-2 Entry into Cells. <i>Nutrients</i> , 2022, 14, 3417.	1.7	12
322	Immunomodulatory therapies for COVID-19. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	3
323	Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	78
324	Atorvastatin for reduction of 28-day mortality in hospitalized COVID-19 patients: study protocol for a randomized, double-blinded, placebo-controlled, clinical trial. <i>Trials</i> , 2022, 23, .	0.7	2
325	The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	5

#	ARTICLE	IF	CITATIONS
326	Clinical implications of vascular dysfunction in acute and convalescent COVID-19: A systematic review. <i>European Journal of Clinical Investigation</i> , 2022, 52, .	1.7	12
327	In Vitro Evidence of Statins' Protective Role against COVID-19 Hallmarks. <i>Biomedicines</i> , 2022, 10, 2123.	1.4	3
328	N-3 polyunsaturated fatty acids may affect the course of COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
329	Perceived health literacy and COVID-19 vaccine acceptance among Chinese college students: A mediation analysis. <i>PLoS ONE</i> , 2022, 17, e0273285.	1.1	7
330	Atorvastatin Efficacy in the Management of Mild to Moderate Hospitalized COVID-19: A Pilot Randomized Triple-blind Placebo- controlled Clinical Trial. <i>Recent Advances in Anti-Infective Drug Discovery</i> , 2022, 17, 212-222.	0.4	11
331	The potential molecular implications of adiponectin in the evolution of SARS-CoV-2: Inbuilt tendency. <i>Journal of King Saud University - Science</i> , 2022, 34, 102347.	1.6	12
332	Systematic Review and Meta-Analysis of Statin Use and Mortality, Intensive Care Unit Admission and Requirement for Mechanical Ventilation in COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 5454.	1.0	9
333	Linking research of biomedical datasets. <i>Briefings in Bioinformatics</i> , 0, , .	3.2	0
334	Statin therapy may protect against acute kidney injury in patients hospitalized for interstitial SARS-CoV2 pneumonia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2023, 33, 227-231.	1.1	1
335	Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 695-709.	2.8	105
336	Statin Therapy to Improve Outcome of COVID-19 Patients: Useful or Not Useful?. <i>Journal of Personalized Medicine</i> , 2022, 12, 1627.	1.1	0
337	Phenotypical and Functional Alteration of \hat{T} T Lymphocytes in COVID-19 Patients: Reversal by Statins. <i>Cells</i> , 2022, 11, 3449.	1.8	0
338	COVID-19 outcomes in patients taking cardioprotective medications. <i>PLoS ONE</i> , 2022, 17, e0275787.	1.1	3
339	LIGHTHOUSE illuminates therapeutics for a variety of diseases including COVID-19. <i>IScience</i> , 2022, 25, 105314.	1.9	3
340	Hospitalisation for COVID-19 predicts long lasting cerebrovascular impairment: A prospective observational cohort study. <i>NeuroImage: Clinical</i> , 2022, 36, 103253.	1.4	5
341	Shared genetic influences between blood analyte levels and risk of severe COVID-19. <i>Cell Reports</i> , 2022, 41, 111708.	2.9	1
342	Effect of regular statin intake on the development of cardiovascular events in the acute period of COVID-19 and within three months after discharge from the infectious diseases hospital. Part 1. Analysis of patients with fatal outcome during hospitalization. , 2022, 21, 58-66.	0.0	1
343	An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	11

#	ARTICLE	IF	CITATIONS
344	Facts and ideas on statins with respect to their lipophilicity: a focus on skeletal muscle cells and bone besides known cardioprotection. <i>Molecular and Cellular Biochemistry</i> , 0, , .	1.4	1
345	Sleep and circadian rhythm disruption alters the lung transcriptome to predispose to viral infection. <i>IScience</i> , 2023, 26, 105877.	1.9	5
346	Outcome of COVID-19 infection in people with diabetes mellitus or obesity in the primary care setting in Catalonia, Spain: A retrospective cohort study of the initial three waves. <i>Primary Care Diabetes</i> , 2022, , .	0.9	1
347	Viral modulation of lipid rafts and their potential as putative antiviral targets. <i>Reviews in Medical Virology</i> , 2023, 33, .	3.9	5
348	Effect of regular statin intake on the development of cardiovascular events in the acute period of COVID-19 and within three months after discharge from the infectious diseases hospital. Part II. Analysis of patients discharged from the infectious diseases hospital. , 2022, 21, 58-68.	0.0	0
349	Renin-Angiotensin-Aldosterone axis inhibition improves outcome of diabetic patients with chronic hypertension and COVID-19: An Iranian perspective. <i>Advanced Biomedical Research</i> , 2022, 11, 109.	0.2	0
350	Lithium treatment extends human lifespan: findings from the UK Biobank. <i>Aging</i> , 2022, 15, 421-440.	1.4	6
351	PCSK9: The Nexus of Lipoprotein Metabolism and Inflammation in COVID-19. <i>Journal of the American College of Cardiology</i> , 2023, 81, 235-236.	1.2	5
352	A Review on COVID-19: Primary Receptor, Endothelial Dysfunction, Related Comorbidities, and Therapeutics. , 0, , .		0
354	Correlation between Medications Used during COVID Infection and Post-conditions after the Acute Phase of Infection: A Cross-sectional Study. <i>Open Public Health Journal</i> , 2022, 15, .	0.1	0
355	SKI-1/S1P Facilitates SARS-CoV-2 Spike Induced Cell-to-Cell Fusion via Activation of SREBP-2 and Metalloproteases, Whereas PCSK9 Enhances the Degradation of ACE2. <i>Viruses</i> , 2023, 15, 360.	1.5	3
356	Efficacy and safety of metabolic interventions for the treatment of severe COVID-19: in vitro, observational, and non-randomized open-label interventional study. <i>ELife</i> , 0, 12, .	2.8	5
357	Invasive Mechanical Ventilation and Death Was More Likely in Patients with Lower LDL Cholesterol Levels during COVID-19 Hospitalization: A Retrospective Propensity-Matched Cohort Study. <i>Journal of Respiration</i> , 2023, 3, 39-48.	0.4	0
358	Interaction of Anti-COVID-19 Drugs with Cardiovascular Therapy. <i>Contemporary Cardiology</i> , 2022, , 255-261.	0.0	0
359	Fenofibrate and Statins in Patients with COVID-19. <i>Research Journal of Pharmacy and Technology</i> , 2022, , 5132-5138.	0.2	0
360	Inflammaging as a target for healthy ageing. <i>Age and Ageing</i> , 2023, 52, .	0.7	22
361	The intersection of obesity and (long) COVID-19: Hypoxia, thrombotic inflammation, and vascular endothelial injury. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	17
362	Potential antiviral effects of pantethine against SARS-CoV-2. <i>Scientific Reports</i> , 2023, 13, .	1.6	2

#	ARTICLE	IF	CITATIONS
363	Characteristics, Mortality, and Clinical Outcomes of Hospitalized Patients with COVID-19 and Diabetes: A Reference Single-Center Cohort Study from Poland. <i>International Journal of Endocrinology</i> , 2023, 2023, 1-11.	0.6	3
364	Integrative network pharmacology and in silico analyses identify the anti-omicron SARS-CoV-2 potential of eugenol. <i>Heliyon</i> , 2023, 9, e13853.	1.4	4
365	Association of statin use with outcomes of patients admitted with COVID-19: an analysis of electronic health records using superlearner. <i>BMC Infectious Diseases</i> , 2023, 23, .	1.3	4
366	Treating COVID-19: Targeting the Host Response, Not the Virus. <i>Life</i> , 2023, 13, 712.	1.1	2
367	Impact of in-hospital statin use on mortality in COVID-19 patients from a majority African American population. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2024, 64, 137-141.	0.8	1
368	Association of Cardiovascular Medications With Adverse Outcomes in a Matched Analysis of a National Cohort of Patients With COVID-19. , 2023, 9, 100040.		3
369	Dual insulin resistance causes: how frequently type 2 diabetes mellitus and COVID-19 infection caused diabetic ketoacidosis? a case report. <i>Annals of Medicine and Surgery</i> , 2023, 85, 1096-1099.	0.5	5
371	Long-Term Exposure to Fine Particulate Constituents and Vascular Damage in a Population with Metabolic Abnormality in China. <i>Journal of Atherosclerosis and Thrombosis</i> , 2023, 30, 1552-1567.	0.9	3
372	Diabetes as one of the long-term COVID-19 complications: from the potential reason of more diabetic patients's susceptibility to COVID-19 to the possible caution of future global diabetes tsunami. <i>Inflammopharmacology</i> , 2023, 31, 1029-1052.	1.9	4
389	Chromogranin A and its derived peptides: potential regulators of cholesterol homeostasis. <i>Cellular and Molecular Life Sciences</i> , 2023, 80, .	2.4	1
395	A Review of Statins and COVID-19. , 0, , .		0
397	Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside. <i>Signal Transduction and Targeted Therapy</i> , 2024, 9, .	7.1	1